Latest studies
- RecruitingPhase II/III
A trial assessing preoperative chemotherapy in patients with locally advanced but operable colon cancer
The FOxTROT trials look at whether giving bowel cancer treatments, such as chemotherapy or immunotherapy, before surgery helps shrink tumours and stops cancer returning. The study tests this approach in people of different ages, fitness levels, and tumour types to see who benefits the most.
Locally advanced but operable colon cancerSweden - RecruitingPhase II
A study to learn if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
This study is testing a new capsule called ZED1227 for adults with coeliac disease. Researchers want to see if this medicine can protect the gut and ease lingering tummy symptoms caused by accidental gluten exposure, even in people who already follow a strict gluten-free diet.
Coeliac diseaseSweden - RecruitingPhase I/II
A trial looking at different treatments for neuroblastoma which has come back after initial therapy
The BEACON2 trial is testing new combinations of cancer medicines for children and young people whose neuroblastoma has returned or worsened after initial treatment. The goal is to find out which drug combinations are safest and work best to control the disease and improve future care.
Relapsed NeuroblastomaSweden - CompletedPhase III
A randomized, open-label phase 3 study of amivantamab + FOLFIRI versus cetuximab/bevacizumab + FOLFIRI in participants with KRAS/NRAS and BRAF wildtype recurrent, unresectable or metastatic colorectal cancer who have received prior chemotherapy
This clinical trial is testing a new targeted drug, amivantamab, combined with chemotherapy for people with advanced bowel cancer. Researchers want to see if this combination works better at slowing cancer growth and helping people live longer than current standard targeted treatments after their first chemotherapy has stopped working.
Recurrent, unresectable or metastatic colorectal cancerSweden - CompletedPhase II
Testing new medicine for adults with Cystic Fibrosis who do not have access to the currently available CFTR-modulating drugs due to genetic mutations
This clinical trial tests a new three-in-one medicine for adults with cystic fibrosis who have rare genetic mutations. These patients cannot access currently approved treatments. Researchers are checking whether this daily combination of capsules can safely improve lung health after promising results in laboratory tests using patient cell samples.
Treatment of Cystic Fibrosis (CF) in patients with CFTR mutations who are responders in the organoid assaySweden - RecruitingPHASE3
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study is testing a new medicine, plozasiran, for people with very high triglycerides who have had pancreatitis. It will check if the medicine is safe and helps reduce the risk of future pancreatitis attacks. Participants will get either the study medicine or a dummy medicine.
Severe HypertriglyceridemiaSweden - RecruitingPHASE3
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
This study looks at a new drug, elritercept, for people with myelofibrosis and anaemia who are already taking ruxolitinib. It compares elritercept to a dummy drug (placebo) to see if it improves anaemia and other symptoms, and how safe it is.
MyelofibrosisAnemiaSweden - RecruitingPHASE2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This study is testing a new medicine called belzutifan for certain types of advanced cancers, including rare adrenal gland, gut, and kidney cancers. We want to see how well it works and if it's safe for people aged 12 and over.
Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau DiseaseAdvanced Gastrointestinal Stromal TumorSweden - RecruitingPhase III
Tranexamic acid (and Desmopressin) for very early bleeds in the brain
This clinical trial tests whether an affordable medicine called tranexamic acid can stop bleeding in the brain after a stroke. Doctors want to see if giving this injection quickly in the emergency room helps people survive with less long-term disability, improving recovery and everyday life six months later.
Hyperacute primary intracerebral haemorrhage (stroke)Sweden - Recruiting
Optimal personalised treatment of early breast cancer using multiparameter analysis
This study looks at whether a specialised tumour test can help women with early breast cancer safely avoid chemotherapy. Researchers want to see if hormone therapy alone works just as well for some women, sparing them difficult side effects without increasing the risk of their cancer returning.
Breast cancerSweden - RecruitingPhase I
Deferred registration - ICON Clinical (UK) Limited/Newcastle Upon Tyne Hospitals NHS Foundation Trust Code: BP45361
This is an early-stage Phase 1 clinical trial taking place in the UK with Newcastle Upon Tyne Hospitals NHS Foundation Trust. Full details about the study are temporarily withheld under official UK research rules. The study plans to include men and women aged between 40 and 75 years.
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.Sweden - CompletedPhase II/III
ENRICH Ibrutinib for untreated mantle cell lymphoma
The ENRICH study is testing a targeted medicine called ibrutinib for people aged 60 and older who have newly diagnosed mantle cell lymphoma. Researchers want to see if ibrutinib, taken with an antibody drug, works better and causes fewer side effects than traditional chemotherapy.
Mantle cell lymphoma (MCL)Sweden - AuthorisedTherapeutic use (Phase IV)
Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program
This study monitors the long-term safety of a gene therapy called Libmeldy in adults treated for metachromatic leukodystrophy (MLD). Doctors collect blood and tissue samples to check for very rare risks, such as abnormal cell growth or cancer, helping to ensure the treatment remains safe over time.
Metachromatic leukodystrophySweden - AuthorisedHuman Pharmacology (Phase I)- Other
A clinical trial comparing how the body takes up budesonide from different forms of medicine when taken by mouth with or without food.
This early-stage study looks at how the body absorbs a steroid medicine called budesonide. Researchers want to compare different oral forms of the medicine and see if taking them with or without food changes how well they work to treat inflammation in the food pipe (eosinophilic oesophagitis).
Acute eosinophilic esophagitisSweden - AuthorisedTherapeutic exploratory (Phase II)
Inducing durable immunological control of HIV-1 through administration of long-acting broadly neutralizing antibodies and low-dose anti-PD-1 – a randomized, double-blinded, placebo-controlled trial (the IDUNN trial)
This study tests whether a combination of specialised immune proteins and an immune-boosting drug can control HIV without daily medication. Participants carefully pause their usual tablets under close medical monitoring to see if the new treatments can keep the virus suppressed on their own.
HIV-1 diseaseSweden - AuthorisedTherapeutic confirmatory (Phase III)
Paracervical block with ropivacaine for pain relief in second trimester medical abortion - a double blind placebo controlled randomized trial
This clinical trial is testing whether a local numbing injection, called ropivacaine, reduces pain during a second-trimester medical abortion. Researchers are comparing this numbing medicine with an inactive salt-water injection to see if it helps lower pain scores during the procedure for women aged 18 and older.
abortionSweden - RecruitingTherapeutic exploratory (Phase II)
A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
This clinical trial looks at whether combining two medicines, eplontersen and ALXN2220, is safe and effective for adults with a heart condition called ATTR-CM. Researchers want to find out if using both treatments together helps improve breathing, exercise fitness, and overall heart health better than taking eplontersen with a dummy drug.
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)Sweden - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
This clinical trial is studying a medicine called crinecerfont for adults with classic congenital adrenal hyperplasia (CAH). CAH causes the body to make too much male hormone. Researchers want to see if this daily medicine can safely lower these hormone levels over 24 weeks without needing high steroid doses.
Classic Congenital Adrenal Hyperplasia (CAH)Sweden - AuthorisedTherapeutic use (Phase IV)
Patient-Controlled Anesthesia for endoscopic Procedural Sedation – PCAPS study
This study looks at a patient-controlled button for sedation during an endoscopy to remove non-cancerous growths called adenomas. Researchers want to see if letting patients manage their own relaxing medication helps them feel more comfortable, reduces recovery time, and leads to a better overall hospital experience.
AdenomaSweden - AuthorisedTherapeutic exploratory (Phase II)
An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer’s Disease
This clinical trial tests a new potential medicine called TML-6 for people living with early Alzheimer’s disease. Researchers want to see if it is safe and whether it can help slow down memory loss over one year. Participants will receive either the study medicine or an inactive dummy pill (placebo).
Early Alzheimer’s DiseaseSweden - AuthorisedTherapeutic exploratory (Phase II)
HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma
This study looks at a new drug combination for older or frail adults with diffuse large B-cell lymphoma, a type of blood cancer. Researchers want to see if adding an antibody drug called epcoritamab to standard, gentler chemotherapy helps clear the cancer better and keeps people well for longer.
Diffuse large B-cell lymphoma (DLBCL)Sweden - AuthorisedHuman Pharmacology (Phase I)- First administration to humans
First-in-human evaluation of [11C]UCB-1A as imaging marker for synaptic vesicle glycoprotein 2C (SV2C): a PET study in healthy volunteers and participants with Parkinson’s disease
This early-stage study tests a new brain imaging tracer called [11C]UCB-1A. Researchers want to see if this tracer can safely show a specific brain protein on PET scans in both healthy volunteers and people with Parkinson’s disease. It aims to improve how doctors study and track brain health.
Parkinson's diseaseSweden - AuthorisedTherapeutic exploratory (Phase II)
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
This study looks at non-small cell lung cancer that can be treated with surgery. Researchers want to find out if having an immunotherapy drug called Imfinzi after surgery helps stop the cancer from returning, following initial chemo-immunotherapy before surgery. It aims to see if extra treatment improves long-term health.
Non Small Cell Lung Cancer (NSCLC)Sweden - AuthorisedTherapeutic exploratory (Phase II)
Randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of 2 dose levels of the oral ghrelin receptor agonist AC01 over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF)
This study tests a new daily tablet called AC01 for people with long-term heart failure. Researchers want to see if this medicine can help the heart pump blood more effectively. Participants take either the real medicine or a dummy tablet for 12 weeks while doctors monitor their heart health.
chronic advanced heart failure with reduced ejection fraction (HFrEF)Sweden - AuthorisedPhase II and Phase III (Integrated)
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)
This clinical study tests a new tablet called atumelnant for adults with ACTH-dependent Cushing's syndrome. In this condition, the body makes too much cortisol hormone. Researchers want to see if different doses of atumelnant can safely bring cortisol levels back to normal within 12 weeks and improve everyday wellbeing.
• ACTH-Dependent Cushing’s Syndrome.• Pituitary-dependent Cushing´s syndrome.Sweden - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, DoubleBlind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension (PALM-PAH)
This study is testing a new once-daily dry powder inhaler called treprostinil palmitil for pulmonary arterial hypertension (high blood pressure in the lungs). Doctors want to see if inhaling this medicine once a day helps people walk further and improves their daily symptoms compared with a dummy medicine (placebo).
Pulmonary Arterial HypertensionSweden - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies
This study tests whether a new medicine called rocatinlimab helps adults with prurigo nodularis. This skin condition causes intensely itchy, firm lumps to form on the skin. The trial checks if the treatment can reduce severe itching and heal skin bumps when prescription creams have not provided enough relief.
Prurigo NodularisSweden - RecruitingTherapeutic exploratory (Phase II)
Morphine effects on stress response and social interaction – an exploratory randomized controlled experimental medicine study
This study looks at how morphine affects the brain and body during social stress. Researchers want to see if this pain-relief medicine can reduce the emotional sting of being left out. Healthy adult volunteers will receive either a dose of morphine or a dummy saltwater drip before having a brain scan.
Healthy volunteersSweden - AuthorisedTherapeutic exploratory (Phase II)
Neo-adjuvant versus Adjuvant chemotherapy in Upper Tract Urothelial Carcinoma: A feasibility phase II randomized clinical trial (“URANUS”)
This study looks at cancer in the upper urinary tract. Doctors want to see whether it is better for patients to have chemotherapy before surgery or after surgery. The aim is to find out which timing allows more people to complete their full three courses of treatment safely.
Upper Tract Urothelial Carcinoma. Upper urinary tract transitional cell carcinomaSweden - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
This study is testing a new injection called ION-682884 for adults with a serious heart condition called ATTR-CM. Researchers want to find out if this medicine can protect the heart, lower the need for hospital care, and help people live longer compared to a dummy treatment (placebo).
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)Sweden - RecruitingTherapeutic confirmatory (Phase III)
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
This study looks at a medicine called nemolizumab for adults with prurigo nodularis. Prurigo nodularis is a skin condition that causes hard, very itchy lumps. Doctors want to see if nemolizumab is safe and effective at calming severe itch and clearing skin nodules over a longer period.
Prurigo NodularisSweden - RecruitingPHASE3
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
This study is looking at a new medicine called Danicamtiv for people with a heart condition called genetic or familial Dilated Cardiomyopathy (DCM). It wants to see how well the medicine works over a long time, if it's safe, and if people can take it easily. There are currently no specific medicines for this type of DCM.
Symptomatic Genetic Dilated Cardiomyopathy (DCM)Sweden - RecruitingTherapeutic confirmatory (Phase III)
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
This study looks at two medicines, rucaparib and nivolumab, for women with advanced ovarian, fallopian tube, or primary peritoneal cancer. It aims to see if using these drugs after standard chemotherapy helps keep the cancer away for longer compared to dummy treatments, known as placebos.
Ovarian epithelialcancer, Malignant peritonealneoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopiantube, or primary peritoneal cancer (who responded to front-lineSweden - RecruitingPhase II and Phase III (Integrated)
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
This clinical trial is testing a new injection called efgartigimod for adults with inflammatory muscle disease (myositis). Researchers want to see if the medicine can safely reduce muscle inflammation, improve strength, and help people lower their daily steroid dose compared to a dummy treatment over 52 weeks.
Active Idiopathic Inflammatory Myopathy (IIM)Sweden - RecruitingHuman Pharmacology (Phase I)- Other
A Phase 1 open-label positron emission tomography TRIAL to assess changes in liver uptake of [68Ga]Ga-FAPI-46 following oral administration of single doses of AZD2389 to patients with advanced liver fibrosis (PECHORA)
This early-stage study looks at a new experimental medicine called AZD2389 for advanced liver scarring (fibrosis). Researchers use special liver scans to see how a single dose travels through the body and affects active scarring cells. This helps scientists understand if the drug works as intended.
advanced liver fibrosisSweden - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease
This study tests whether a medicine called efgartigimod can help adults with primary Sjögren’s disease. Researchers want to see if regular injections under the skin can ease symptoms like joint pain, dry eyes, and dry mouth, and lower overall body inflammation compared with a dummy treatment (placebo).
Primary Sjögren’s DiseaseSweden - Not yet recruitingPHASE3
Study With Batten-1 (Miglustat Liquid Formulation) to Treat Ceroid Lipofuscinosis Neuronal 3 (CLN3) Disease
This clinical trial is testing a liquid medicine called Batten-1 (miglustat) for children and teenagers with CLN3 Batten disease. Researchers want to see if taking this medicine every day can help slow down or stop vision loss, while checking for any side effects and monitoring overall wellbeing.
CLN3Sweden - RecruitingTherapeutic exploratory (Phase II)
An exploratory, randomized, double-blind, multicentre, placebo-controlled study of RTP-026 to assess safety, tolerability, and efficacy in patients with ST-Elevation Myocardial Infarction (STEMI)
This study looks at a new medicine called RTP-026 for adults who have had a severe heart attack. Researchers want to see if it helps protect heart muscle after an emergency procedure to clear blocked arteries, and whether it is safe and well tolerated.
Patients with ST-Elevation Myocardial Infarction (STEMI)Sweden - RecruitingTherapeutic confirmatory (Phase III)
A Phase III, double-blind, randomized, placebo-controlled multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy (ADAURA)
This clinical trial looks at a daily tablet called Tagrisso (osimertinib) for adults who have had surgery to remove early-stage lung cancer. Researchers want to see if taking Tagrisso helps stop the cancer from returning compared to an inactive dummy tablet (placebo) in tumours with an EGFR gene change.
Sweden - RecruitingTherapeutic exploratory (Phase II)
Effect of Exenatide on disease progression in early Parkinson’s disease.
This clinical trial is testing whether a medicine called exenatide can slow down early Parkinson's disease. Normally used for diabetes, researchers want to see if weekly injections of this drug can protect brain cells over a 21-month period, using specialised brain scans and regular movement checks.
Parkinson's diseaseSweden - AuthorisedTherapeutic confirmatory (Phase III)
A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, versus Placebo in Participants with Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)
This clinical study tests two new medicines, REGN7508 and REGN9933, for adults with atrial fibrillation (an irregular heartbeat). It aims to find out if these treatments can safely stop blood clots and strokes in people who cannot take standard blood-thinning tablets due to a high risk of bleeding.
Atrial Fibrillation (AF)Sweden - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human) in Subjects with Pulmonary Emphysema due to Alpha1-Antitrypsin Deficiency
This study tests whether a weekly drip of a protein medicine can protect the lungs in adults with alpha-1 antitrypsin deficiency. Researchers want to see if two different doses can slow down lung damage and reduce severe chest flare-ups compared to a dummy treatment.
Pulmonary Emphysema due to Alpha-1-Antitrypsin DeficiencySweden - RecruitingTherapeutic exploratory (Phase II)
SYNERGY OSA - EFFICACY, SAFETY and TOLERABILITY OF COMBINED THERAPY WITH A SOMNOMED ORAL APPLIANCE AND THE CARBONIC ANHYDRASE INHIBITOR SULTHIAME IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA. A Randomized, Double-Blind, Placebo Controlled, Proof-of-Concept Trial
This study tests whether adding a tablet called sulthiame to a standard dental sleep splint helps treat obstructive sleep apnoea. Researchers want to see if this combined treatment reduces nighttime breathing pauses and improves daytime energy better than a dummy tablet in adults whose splint is not fully working.
Obstructive sleep apnea with an incomplete clinical response to oral appliance therapy.Sweden - RecruitingTherapeutic confirmatory (Phase III)
The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency
The ENERGY 2 study is testing a new medicine called INZ-701 for babies with ENPP1 deficiency. This rare condition can cause harmful calcium build-up in blood vessels and heart problems. Researchers want to see if INZ-701 is safe, protects the heart, and helps babies grow well over one year.
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) DeficiencySweden - RecruitingTherapeutic confirmatory (Phase III)
An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
This study looks at a medicine called sotatercept for adults with pulmonary arterial hypertension (PAH). Researchers want to see how safe it is over a longer period when taken alongside usual treatments. It also checks whether the medicine helps improve walking ability, heart health, and everyday energy levels.
Pulmonary Arterial Hypertension (PAH)Sweden - RecruitingTherapeutic exploratory (Phase II)
A randomized controlled trial with Rituximab for Psychotic disorder in adults
This clinical trial is looking at whether a medicine called rituximab can help adults with schizophrenia spectrum disorders. Researchers want to see if this treatment improves day-to-day symptoms, emotional well-being, and social functioning, using standard medical interviews and checks to measure any changes in how people feel.
Schizophrenia spectrum disorder (SSD)Sweden - RecruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome (NEPTUNUS-2)
This study tests a new medicine called ianalumab for adults with active Sjögren's syndrome. Researchers want to see if regular injections can calm the immune system, ease severe tiredness, and improve dry eyes and mouth compared to a dummy jab (placebo) over 48 weeks of treatment.
Sjögren’s SyndromeSweden - RecruitingTherapeutic confirmatory (Phase III)
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia
This clinical trial looks at new treatments for adults with chronic lymphocytic leukaemia (CLL) who have not had treatment before. It compares a targeted drug called acalabrutinib, taken alone or with an antibody drip, against standard chemotherapy to find out which option controls leukaemia best and causes fewer side effects.
Chronic Lymphocytic LeukemiaSweden - AuthorisedTherapeutic exploratory (Phase II)
Interventional, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose trial of Lu AF28996 in adults with Parkinson’s disease experiencing motor fluctuations.
This clinical trial is testing a new experimental medicine called Lu AF28996 for adults with Parkinson's disease. Researchers want to see if this treatment can increase daily 'good ON time'—the hours when symptoms are well controlled without causing troublesome, involuntary movements—compared to a dummy pill (placebo).
Parkinson’s diseaseSweden - AuthorisedHuman Pharmacology (Phase I)- First administration to humans
A double-blind, prospective, randomised, placebo-controlled, single-centre, proof-of-principle trial in healthy volunteers to investigate safety, local tolerability, pharmacokinetics, and pharmacodynamics of Asacaine after topical administration on skin exposed to ultraviolet B radiation
This early-stage study tests a new pain-relief cream called Asacaine on healthy volunteers. Researchers use a mild dose of ultraviolet B (UVB) light to create temporary, sunburn-like skin tenderness. They then check how safe Asacaine is, how well the skin tolerates it, and if it eases mild skin pain.
Topical painSweden